Literature DB >> 7957428

Pentoxifylline treatment of sepsis of premature infants: preliminary clinical observations.

R Lauterbach1, D Pawlik, B Tomaszczyk, B Cholewa.   

Abstract

Pentoxifylline (Trental, 5 mg/kg/h for 6 h) was administered to 17 premature infants with sepsis, on 3 successive days. A statistically significant decrease in mortality rate (P < 0.04) was observed in comparison to a retrospectively analysed group of 13 septic infants, who were treated in a comparative way but without the use of a pentoxifylline infusion. The suggestion that pentoxifylline may be an effective drug in the treatment of Gram-negative sepsis in premature infants should be tested in a double-blind, randomized study.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957428     DOI: 10.1007/BF02190690

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  8 in total

1.  Oxpentifylline in endotoxaemia.

Authors:  P Zabel; D T Wolter; M M Schönharting; U F Schade
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

2.  Pentoxifylline treatment of persistent pulmonary hypertension of newborn.

Authors:  R Lauterbach
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

3.  Correlation of plasma cytokine elevations with mortality rate in children with sepsis.

Authors:  J S Sullivan; L Kilpatrick; A T Costarino; S C Lee; M C Harris
Journal:  J Pediatr       Date:  1992-04       Impact factor: 4.406

4.  Effects of in vivo pentoxifylline treatment on survival and ex vivo vascular contractility in a rat lipopolysaccharide shock model.

Authors:  M A Fletcher; T M McKenna; E H Owens; V M Nadkarni
Journal:  Circ Shock       Date:  1992-01

5.  Pentoxifylline lessens the endotoxin-induced increase in albumin clearance across pulmonary artery endothelial monolayers with and without neutrophils.

Authors:  K Sato; T J Stelzner; R F O'Brien; J V Weil; C H Welsh
Journal:  Am J Respir Cell Mol Biol       Date:  1991-03       Impact factor: 6.914

6.  Pretreatment with pentoxifylline improves the hemodynamic and histologic changes and decreases neutrophil adhesiveness in a pig fecal peritonitis model.

Authors:  D Tighe; R Moss; J Hynd; S Boghossian; N al-Saady; M F Heath; E D Bennett
Journal:  Crit Care Med       Date:  1990-02       Impact factor: 7.598

7.  Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells.

Authors:  L Schandené; P Vandenbussche; A Crusiaux; M L Alègre; D Abramowicz; E Dupont; J Content; M Goldman
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

8.  Increases in tumor response by pentoxifylline alone or in combination with nicotinamide.

Authors:  I Lee; J H Kim; S H Levitt; C W Song
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

  8 in total
  5 in total

1.  Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis.

Authors:  R Lauterbach; M Zembala
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

Review 2.  Pentoxifylline in preterm neonates: a systematic review.

Authors:  Emma Harris; Sven M Schulzke; Sanjay K Patole
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

Review 3.  New modalities for treating neonatal infection.

Authors:  A R Bedford-Russell
Journal:  Eur J Pediatr       Date:  1996-08       Impact factor: 3.183

4.  Pentoxifylline as an adjunct therapy in children with cerebral malaria.

Authors:  Bertrand Lell; Carsten Köhler; Betty Wamola; Christopher Ho Olola; Esther Kivaya; Gilbert Kokwaro; David Wypij; Sadik Mithwani; Terrie E Taylor; Peter G Kremsner; Charles R J C Newton
Journal:  Malar J       Date:  2010-12-21       Impact factor: 2.979

5.  Protocol: Pentoxifylline optimal dose finding trial in preterm neonates with suspected late onset sepsis (PTX-trial).

Authors:  Serife Kurul; H Rob Taal; Robert B Flint; Jan Mazela; Irwin K M Reiss; Karel Allegaert; Sinno H P Simons
Journal:  BMC Pediatr       Date:  2021-11-18       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.